These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31776464)

  • 1. Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.
    Caye A; Rouault-Pierre K; Strullu M; Lainey E; Abarrategi A; Fenneteau O; Arfeuille C; Osman J; Cassinat B; Pereira S; Anjos-Afonso F; Currie E; Ariza-McNaughton L; Barlogis V; Dalle JH; Baruchel A; Chomienne C; Cavé H; Bonnet D
    Leukemia; 2020 Jun; 34(6):1658-1668. PubMed ID: 31776464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
    Louka E; Povinelli B; Rodriguez-Meira A; Buck G; Wen WX; Wang G; Sousos N; Ashley N; Hamblin A; Booth CAG; Roy A; Elliott N; Iskander D; de la Fuente J; Fordham N; O'Byrne S; Inglott S; Norfo R; Salio M; Thongjuea S; Rao A; Roberts I; Mead AJ
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33416891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
    Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
    Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
    Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
    Elife; 2022 May; 11():. PubMed ID: 35535491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group.
    Bresolin S; De Filippi P; Vendemini F; D'Alia M; Zecca M; Meyer LH; Danesino C; Locatelli F; Masetti R; Basso G; Te Kronnie G
    Oncotarget; 2016 May; 7(20):28914-9. PubMed ID: 26980750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
    De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
    Chang TY; Dvorak CC; Loh ML
    Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients.
    Coppe A; Nogara L; Pizzuto MS; Cani A; Cesaro S; Masetti R; Locatelli F; Te Kronnie G; Basso G; Bortoluzzi S; Bresolin S
    Hum Mutat; 2018 Apr; 39(4):579-587. PubMed ID: 29316027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
    Gandre-Babbe S; Paluru P; Aribeana C; Chou ST; Bresolin S; Lu L; Sullivan SK; Tasian SK; Weng J; Favre H; Choi JK; French DL; Loh ML; Weiss MJ
    Blood; 2013 Jun; 121(24):4925-9. PubMed ID: 23620576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
    Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile myelomonocytic leukemia.
    Proytcheva M
    Semin Diagn Pathol; 2011 Nov; 28(4):298-303. PubMed ID: 22195407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
    De Filippi P; Zecca M; Novara F; Lisini D; Maserati E; Pasquali F; Rosti V; Carlo-Stella C; Zavras N; Cagioni C; Zuffardi O; Pagliara D; Danesino C; Locatelli F
    Pediatr Blood Cancer; 2012 Sep; 59(3):580-2. PubMed ID: 22183880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.